Kindred Biosciences, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $4.3M | $2.0M | $0 | $0 | — |
| Operating income | −$20.0M | −$62.6M | −$51.3M | −$31.7M | −$22.8M | −$27.3M |
| Net income | −$21.8M | −$61.4M | −$49.7M | −$30.9M | −$22.5M | −$27.1M |
| Total assets | $95.8M | $114.0M | $106.5M | $90.8M | $61.6M | $79.6M |
| Total liabilities | $28.3M | $32.1M | $15.3M | $6.1M | $3.9M | $3.2M |
| Equity | $67.5M | $81.9M | $91.2M | $84.7M | $57.7M | $76.4M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 39.3M | 38.9M | 28.2M | 22.1M | 19.8M | 19.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −47.4%
- Net margin
- −51.7%
- Return on equity
- −32.3%
- Return on assets
- −22.7%
- Return on capital (ROCE)
- −22.5%
- Liabilities / assets
- 29.6%
- Debt / equity
- 0.42×
- Book value / share
- $1.72
- Revenue growth (YoY)
- 890.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -3.42distress
- Accruals / assets
- −12.5%clean
- Beneish M-Score
- 4.18elevated
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Park West Asset Management Llc10% owner | Aug 27, 2021 | J | 6.0M | — |
| Chin RichardOfficer — Chief Executive Officer | Aug 27, 2021 | D | 1.7M | $9.25 |
| Wee WendyOfficer — Chief Financial Officer | Aug 27, 2021 | D | 78,613 | $9.25 |
| Bevers DeniseDirector | Aug 27, 2021 | D | 145,835 | $9.25 |
| Zhan HangjunOfficer — Chief Scientific Officer | Aug 27, 2021 | D | 64,306 | $9.25 |
| Townsend RaymondDirector | Aug 27, 2021 | D | 24,928 | $9.25 |
| Elanco Animal Health Inc10% owner | Aug 27, 2021 | Buy | 45.5M | $9.25 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 30, 2021
- Shareholder voteAug 26, 2021
- Other material eventAug 2, 2021
- Entered a material agreementJul 1, 2021
- Shareholder voteJun 24, 2021
- Entered a material agreement · Other material eventJun 16, 2021
- Other material eventJun 2, 2021
- Entered a material agreement · Results of operationsMay 11, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASCHEDULE 13G (AMENDMENT NO. 1)Feb 14, 2022
- SC 13G/AFeb 14, 2022
- SC 13G/ASep 13, 2021
- 4Sep 13, 2021
- 15-12BSep 7, 2021
- EFFECTSep 1, 2021
- SC 13D/AAug 31, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
- 4PRIMARY DOCUMENTAug 30, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.